Elidel
Faslodex
Idarubicin
Entacapone

Kato

Sorry but the fun of spending at $$ on kato for me is now evaporated.

Type or paste links below one per line ; : ex: site ; help me find links done adding cancel kato reads the art of polymer clay creative surface effects: techniques and projects featuring transfers, stamps, stencils, inks, paints, mediums, and more by donna kato amazon price: 57 as of 2008 ; the art of polymer clay: designs and techniques for creating jewelry, pottery, and decorative artwork updated edition ; by donna kato amazon price: 53 as of 2008 ; threefold lotus sutra by bunno kato amazon price: 71 as of 2008 ; kato wear bumper sticker from it' s a calontir thing.
Blood 1998; 91 : 4694– 470 pubmed isi chemport polyak k, kato jy, solomon m, sherr cj, massague j, roberts jm, koff p27kip1, a cyclin-cdk inhibitor, links transforming growth factor- and contact inhibition to cell cycle arrest. Meta-analysis of 2 studies including total 123 cases showed the effect of a-adrenergic antagonists on urinary symptoms of CP CPPS. The combined SMD was 21.60 95% CI 5 22.24 to 20.96 ; Figure 4. The precise mechanisms ofairway hyperreactivity have not been clearly elucidated, it is now widely accepted that a number of mediators released from inflammatory cells into the airways play a role in the development of this hyperreactivity. Among these mediators, platelet activating factor, a phospholipid released from a variety neutrophils, biological of cells including macrophages, eosinophils, and platelets, ' effects on a large range of cell stimulates of human chemotaxis, neutrophils2 basophils, has potent types. For and most.

Zhao Y, Xiao B, Chen B, Qiao T, Fan D. Upregulation of drug sensitivity of multidrug- resistant SGC7901 VCR human gastric cancer cells by bax gene transduction. Chin J Med 2000; 113: 977-980 Ramesh S, Shanthi P, Krishnan KB, Shanthi AV, Taralakshmi VV, Subulakshmi S. Multidrug resistance 1 gene expression in Indian patients with gastric carcinoma. Indian J Gastroenterol 2003; 22: 19-21 Pohl A, Lage H, Muller P, Pomorski T, Herrmann A. Transport of phosphatidylserine via MDR1 multidrug resistance 1 ; Pglycoprotein in a human gastric carcinoma cell line. Biochem J 2002; 365: 259-268 Payen L, Delugin L, Courtois A, Trinquart Y, Guillouzo A, Fardel O. Reversal of MRP -mediated multidrug resistance in human lung cancer cells by the antiprogestatin drug RU486. Biochem Biophys Res Commun 1999; 258: 513-518 Gruol DJ, Zee MC, Trotter J, Bourgeois S. Reversal of multidurg resistance by RU486. Cancer Res 1994; 54: 3088-3091 El Etreby MF, Liang Y, Lewis RW. Induction of apoptosis by mifepristone and tamoxifen in human LNCaP prostate cancer cells in culture. Prostate 2000; 43: 31-42 Cole SP, Bhardwaj G, Gerlach H, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG. Overexpression of a transporter gene in multidrug- resistant human lung cancer cell line. Science 1992; 258: 1650-1654 Kamradt MC, Mohideen N, Vaughan ATM. RU486 increases radiosensitivity and restores apoptosis through modulation of HPV E6 E7 in dexamethasone-treated cervical carcinoma cells. Gynecol Oncol 2000; 77: 177-182 Hotta T, Tanimura H, Iwahashi M, Tani M, Tsunoda T, Noguchi K, Mizobata S, Arii K, Terasawa H, Nakamori M, Yamaue H. Pglycoprotein-expressing tumor cells are resistant to anticancer drugs in human gastrointestinal cancer. Surg Today 1999; 29: 591- Mahajan DK, London SN. Mifepristone RU486 ; : a review. Fertil Steril 1997; 68: 967-976 Basu R, Gundlach T, Tasker M. Mifepristone and misoprostol for medical termination of pregnancy: the effectiveness of a flexible regimen. J Fam Plann Reprod Health Care 2003; 29: 139-141 Rocereto TF, Saul HM, Aikins JA Jr, Paulson J. Phase II study of mifepristone RU486 ; in refractory ovarian cancer. Gynecol Oncol 2000; 77: 429-432 Hyder SM, Chiappetta C, Stancel GM. Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells. Int J Cancer 2001; 92: 469-473 Peters MG, Vanzulli S, Elizalde PV, Charreau EH, Goin MM. Effects of antiprogestins RU486 and ZK98299 on the expression of cell cycle proteins of a medroxyprogesterone acetate MPA ; induced murine mammary tumor. Oncol Rep 2001; 8: 445-449 Yokoyama Y, Shinohara A, Takahashi Y, Wan X, Takahashi S, Niwa K, Tamaya T. Synergistic effects of danazol and mifepristone on the cytotoxicity of UCN-01 in hormone-responsive breast cancer cells. Anticancer Res 2000; 20: 3131-3135 Liang Y, Hou M, Kallab AM, Barrett JT, El Etreby F, Schoenlein PV. Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbeta1. Int J Oncol 2003; 23: 369-380 Stein U, Lage H, Jordan A, Walther W, Bates SE, Litman T, Hohenberger P, Dietel M. Impact of BCRP MXR, MRP1 and MDR1 P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells. Int J Cancer 2002; 97: 751-760 Lin HL, Liu TY, Wu CW, Chi CW. Berberine modulates expression of mdr1 gene product and the responses of digestive track cancer cells to Paclitaxel. Br J Cancer 1999; 81: 416- Alexander D, Yamamoto T, Kato S, Kasai S. Histopathological assessment of multidrug resistance in gastric cancer: expression of P-glycoprotein, multidrug resistance-associated protein, and lung-resistance protein. Surg Today 1999; 29: 401-406 Kim R, Ohi Y, Inoue H, Aogi K, Toge T. Introduction of gadd153 gene into gastric cancer cells can modulate sensitivity to anticancer agents in association with apoptosis. Anticancer Res 1999; 19: 1779-1783 Edited by Ma JY and Xu FM and kava. Induced at a transcriptional level by SA application but rather is regulated posttranslationally by phosphorylation of the SIPK protein Zhang and Klessig, 1997, 1998a, 1998b; Zhang et al., 1998; Romeis et al., 1999 ; . Expression of Sipk did not change significantly in any of the experiments Fig. 5 ; . Transcripts for Aox1, Wipk, Gnt35, and Sagt all increased in abundance after treatment of cells with 0.1 mm SA for 1 and 4 h, with transcript abundance higher after 4 h Fig. 5 ; . Transcript levels for these genes decreased rapidly after 4 h and were very low 24 h after application data not shown ; . Pr1a transcripts, on the other hand, required a 24-h incubation with SA for induction Fig. 5 ; . For comparison, cells were also treated with 5 m of the respiratory poison antimycin. Antimycin exposure for 1 or 4 increased transcript abundance of Aox1 and Wipk to the same level or slightly higher than that following SA exposure for the same time. Antimycin also stimulated Gnt35 expression to some extent but had little effect on the expression of Sagt and Pr1a Fig. 5 ; . To examine the interplay between the SA and antimycin effects, we measured the levels of gene transcripts in cells pretreated for 1 h with 5 m antimycin before incubation with 0.1 mm SA for 1, 4, 7, or 24 h further, depending on the gene. Transcript abundance of Aox1 and Wipk was similar to that induced by antimycin or SA alone. However, the SA-induced increase in transcript abundance for Gnt35, Sagt, and Pr1a was severely inhibited by the pretreatment with antimycin. These results show that some SAresponsive genes, such as Aox1 and Wipk, also respond to an inhibitor of respiratory electron transport, whereas SA-dependent expression of other genes, such as Gnt35, Sagt, and Pr1a, is blocked by this inhibitor. The lack of antimycin inhibition of Sipk, Wipk, and Aox1 transcript accumulation indicates that the lack of message for Gnt35, Sagt, and Pr1a was not due simply to a general decrease or lack of mRNA after disruption of mitochondrial function. The first ophthalmic generic in 1962, the FDA decided that only the generic manufacturer only had to show: 1 ; The active ingredient was the same, 2 ; The indications were the same, 3 ; Any inactive ingredient didn't affect the safety of the proposed drug product, and 4 ; The blood level of the active ingredient had to be 80%-125% of innovator brand ; product. Since 1992, the FDA has required that ophthalmic generics: Contain the same active and inactive ingredients as the brand product. Be within 5% of the brand for bioequivalence or demonstrate bio-equivalence in a head-to-head study. To date, all generics have met the 5% threshold, and none have had to do head-to-head trials. An FDA official explained, "In a three month study.a 95% confidence interval must be shown, and all IOP must be within 1 mmHg." Contain the active brand ingredient in the same concentration with the exception of the preservative, buffer, any substance used to adjust tonicity, thickening agents, provided these do not affect safety. Must show clinical equivalence suspensions, ointments, and gels. for ophthalmic and kenalog. Country: 2544 john mock posted - 02 19 2008 : : 41 well with some of the bozos on this forum now bashing kato on at least 3 different threads-why should they even bother with america. Vitamin D3 analog, EB 1089, with ionizing radiation reduces tumor growth and induces apoptosis of MCF-7 breast tumor xenografts in nude mice. Clin Cancer Res 2003; 9: 2350 Weitsman GE, Ravid A, Liberman UA, Koren R. Vitamin D enhances caspase-dependent and -independent TNFa-induced breast cancer cell death: the role of reactive oxygen species and mitochondria. Int J Cancer 2003; 106: 178 Kim RH, Peters M, Jang Y, et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 2005; 7: 263 Ji Y, Studzinski GP. Retinoblastoma protein and CCAAT enhancerbinding protein h are required for 1, 25-dihydroxyvitamin D3-induced monocytic differentiation of HL60 cells. Cancer Res 2004; 64: 370 Lamb J, Ramaswamy S, Ford HL, et al. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 2003; 114: 323 Studzinski GP, Wang X, Ji Y, et al. The rationale for deltanoids in therapy for myeloid leukemia: role of KSR-MAPK-C EBP pathway. J Steroid Biochem Mol Biol 2005; 97: 47 Oikawa T, Yoshida Y, Shimamura M, Ashino-Fuse H, Iwaguchi T, Tominaga T. Antitumor effect of 22-oxa-1a, 25-dihydroxyvitamin D3, a potent angiogenesis inhibitor, on rat mammary tumors induced by 7, 12dimethylbenz[a]anthracene. Anticancer Drugs 1991; 2: 475 Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE. 1a, 25-dihydroxyvitamin D3 inhibits angiogenesis in vitro and in vivo . Circ Res 2000; 87: 214 Schwartz GG, Wang MH, Zang M, Singh RK, Siegal GP. 1a, 25Dihydroxyvitamin D calcitriol ; inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 1997; 6: 727 Nakagawa K, Sasaki Y, Kato S, Kubodera N, Okano T. 22-Oxa-1a, 25dihydroxyvitaminD3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 2005; 26: 1044 Koli K, Keski-Oja J. 1a, 25-Dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ 2000; 11: 221 Sung V, Feldman D. 1, 25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Mol Cell Endocrinol 2000; 164: 133 Palmer HG, Gonzalez-Sancho JM, Espada J, et al. Vitamin D3 promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of h-catenin signaling. J Cell Biol 2001; 154: 369 Gonzalez-Sancho JM, Alvarez-Dolado M, Munoz A. 1, 25-Dihydroxyvitamin D3 inhibits tenascin-C expression in mammary epithelial cells. FEBS Lett 1998; 426: 225 Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL. Antiproliferative effects of 1a, 25-dihydroxyvitamin D3 and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 2002; 143: 2508 Matsumoto H, Iino Y, Koibuchi Y, et al. Antitumor effect of 22oxacalcitriol on estrogen receptor-negative MDA-MB-231 tumors in athymic mice. Oncol Rep 1999; 6: 349 Palmer HG, Larriba MJ, Garcia JM, et al. The transcription factor SNAIL represses vitamin D receptor expression and responsiveness in human colon cancer. Nat Med 2004; 10: 917 Khanim FL, Gommersall LM, Wood VH, et al. Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells. Oncogene 2004; 23: 6712 Banwell CM, O'Neill LP, Uskokovic MR, Campbell MJ. Targeting 1a, 25-dihydroxyvitamin D3 antiproliferative insensitivity in breast cancer cells by co-treatment with histone deacetylation inhibitors. J Steroid Biochem Mol Biol 2004; 89 90: Colston KW, Pirianov G, Bramm E, Hamberg KJ, Binderup L. Effects of seocalcitol EB1089 ; on nitrosomethyl urea-induced rat mammary tumors. Breast Cancer Res Treat 2003; 80: 303 El Abdaimi K, Dion N, Papavasiliou V, et al. The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res 2000; 60: 4412 Abe-Hashimoto J, Kikuchi T, Matsumoto T, Nishii Y, Ogata E, Ikeda K. Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer Res 1993; 53: 2534 and keppra. 1 Guilleminault C, van den Hoed J, Mitler M. Clinical features and evaluation of obstructive sleep apnea.1994. In Principles and Practice of Sleep Medicine. Kryger M.H., Roth T. Dement W.C. eds. W.B. Saunders Co, Philadelphia; 65: 66777. 2 Schlosshan D and Elliott MW. Sleep. 3: Clinical presentation and diagnosis of the obstructive sleep apnoea hypopnoea syndrome. Thorax 2004; 59: 34752. Jenkinson C, Stradling J, Petersen S. Comparison of three measures of quality of life outcome in the evaluation of continuous positive airways pressure therapy for sleep apnoea. J Sleep Res 1997; 6: 199204. Teran-Santos J, Jimenez-Gomez A, Cordero-Guevara J. The association between sleep apnea and the risk of traffic accidents. Cooperative Group Burgos-Santander [see comments]. N Engl J Med 1999; 340: 84751. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342: 137884. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365: 104653. Yakki HK, Concato J, Kernan WN, Lichtman JHBLM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005; 353: 203441. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993; 328: 12305. Young T, Peppard PE, Taheri S. Excess weight and sleep-disordered breathing. J Appl Physiol 2005; 99: 15929. Douglas NJ. Clinician's guide to sleep medicine. 2002; 1, Arnold, London. 11 Davies RJO, Ali NJ, Stradling JR. Neck circumference and other clinical features in the diagnosis of the obstructive sleep apneoa syndrome. Thorax 1992; 47: 1015. Tsai WH, Remmers JE, Brant R, Flemons WW, Davies J, Macarthur C. A decision rule for diagnostic testing in obstructive sleep apnea. J Respir Crit Care Med 2003; 167: 142732. Ballester E, Badia JR, Hernndez L, Carrasco E, de Pablo J, Fornas C, et al. Evidence of the effectiveness of continuous positive airway pressure in the treatment of sleep apnea hypopnea syndrome. J Respir Crit Care Med 1999; 159: 495501. Sullivan CE, Berthon-Jones M, Issa FG, Eves L. Reversal of obstructive sleep apnea by continuous positive airway pressure applied trough the nares. Lancet 1981; I: 8625. 15 Engleman HM, Martin SE, Deary IJ, Douglas NJ. Effect of continuous positive airway pressure treatment on daytime function in sleep apnoe hypopnoe syndrome. Lancet 1994; 343: 5725. Gordon P and Sanders MH. Sleep 7: Positive airway pressure therapy for obstructive sleep apnoea hypopnoea syndrome. Thorax 2005; 60: 6875. Jenkinson C, Davies RJ, Mullins R, Stradling JR. Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised prospective parallel trial. Lancet 1999; 353: 21005. Montserrat JM, Ferrer M, Hernandez L, Farre R, Vilagut G, Navajas D, et al. Effectiveness of CPAP treatment in daytime function in sleep apnea syndrome: a randomized controlled study with an optimized placebo. J Respir Crit Care Med 2001; 164: 60813. Engleman HM, Kingshott RN, Wraith PK, Mackay TW, Deary IJ, Douglas NJ. Randomized placebo-controlled crossover trial of continuous positive airway pressure for mild sleep Apnea Hypopnea syndrome. J Respir Crit Care Med 1999; 159: 4617. Senn O, Brack T, Matthews F, Russi EW, Bloch KE. Randomized short-term trial of two autoCPAP devices versus fixed continuous positive airway pressure for the treatment of sleep apnea. J Respir Crit Care Med 2003; 168: 150611. Pepperell JC, Ramdassingh-Dow S, Crosthwaite N, Mullins R, Jenkinson C, Stradling JR, et al. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet 2002; 359: 20410. Robinson GV, Pepperell JC, Segal HC, Davies RJ, Stradling JR. Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials. Thorax 2004; 59: 77782. Yokoe T, Minoguchi K, Matsuo H, Oda N, Minoguchi H, Yoshino G, et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003; 107: 112934. Loube DI, Gay PC, Strohl KP, Pack AI, White DP, Collop NA. Indications for positive airway pressure treatment of adult obstructive sleep apnea patients. Chest 1999; 115: 8636. Barbe F, Mayoralas LR, Duran J, Masa JF, Maimo A, Montserrat JM, et al. Treatment with continuous positive airway pressure is not effective in patients with sleep apnea but no daytime sleepiness. a randomized, controlled trial. Ann Intern Med 2001; 134: 101523. Popescu G, Latham M, Allgar V, Elliott MW. Continuous positive airway pressure for sleep apnoea hypopnoea syndrome: usefulness of a 2 week trial to identify factors associated with long term use. Thorax 2001; 56: 72733. Senn O, Brack T, Russi EW, Bloch KE. A continuous positive airway pressure trial as a novel approach to the diagnosis of the obstructive sleep apnea syndrome. Chest 2006; 129: 6775. Kaplan V, Li Y, Hess T, Russi EW, Bloch KE. Compliance mit nasaler Ueberdruckbehandlung CPAP ; bei obstruktiven Schlafapnoe Syndrom. Schweiz Med Wochenschr 1996; 130: 1522. Kribbs NB, Pack AI, Kline LR, Smith PL, Schwartz AR, Schubert NM, et al. Objective measurement of patterns of CPAP use by patients with obstructiv sleep apnea. Rev Respir Dis 1993; 147: 88795. American Sleep Disorders Association. Practice parameters for the treatment of snoring and obstructive sleep apnea with oral appliances. Sleep 1995; 18: 5113. Schmidt-Nowara W, Lowe A, Wiegand L, Cartwright R, PerezGuerra F, Menn S. Oral appliances for the treatment of snoring and obstructive sleep apnea: a review. Sleep 1995; 18: 50110. Lowe AA. Oral appliances for sleep breathing disorders. In Principles and Practice of Sleep Medicine. Kryger M.H., Roth T. Dement W.C. eds. W.B. Saunders Co, Philadelphia; 78: 92939. 33 Bloch KE, Senn O, Iseli A. Oral appliances for treatment of snoring and obstructive sleep apnea. In surgery for sleep apnea. Fabiani M, Saponara M, eds. Kugler Publications, the Hague 2003; 1: 55975. Ferguson KA, Love LL, Ryan CF. Effect of mandibular and tongue protrusion on upper airway size during wakefulness. J Respir Crit Care Med 1997; 155: 174854. Yoshida K. Effect of a prosthetic appliance for treatment of sleep apnea syndrome on masticatory and tongue muscle activity. J Prosthet Dent 1998; 79: 53744. Kato J, Isono S, Tanaka A, Watanabe T, Araki D, Tanzawa H, et al. Dose-dependent effects of mandibular advancement on pharyngeal mechanics and nocturnal oxygenation in patients with sleep-disordered breathing. Chest 2000; 117: 106572. Bloch KE, Iseli A, Zhang JN, Xie X, Stoeckli PW, Russi EW. Randomized, controlled trial of two oral appliances for sleep apnea treatment. J Respir Crit Care Med 2000; 162: 24651. Gotsopoulos H, Chen C, Qian J, and Cistulli PA. Oral appliance therapy improves symptoms in obstructive sleep apnea: a randomized, controlled trial. J Respir Crit Care Med 2002; 166: 7438. Gotsopoulos H, Kelly JJ, Cistulli PA. Oral appliance therapy reduces blood pressure in obstructive sleep apnea: a randomized controlled trial. Sleep 2004; 27: 93441. Barnes M, McEvoy RD, Banks S, Tarquinio N, Murray CG, Vowles N, et al. Efficacy of positive airway pressure and oral appliance in mild to moderate obstructive sleep apnea. J Respir Crit Care Med 2004; 170: 65664. Henke KG, Frantz DE, Kuna ST. An oral elastic mandibular advancement device for obstructive sleep apnea. J Respir Crit Care Med 2000; 161: 4205. Fritsch K, Iseli A, Russi EW, Bloch KE. Side effects of mandibular advancement devices for sleep apnea treatment. J Respir Crit Care Med 2001; 164: 8138. Steinbrook R. Surgery for severe obesity. N Engl J Med 2004; 350: 10759. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 268393.

S! Waunded and maimed nd deprived of- ; Y * ry c h vy$r flnjoying good health, they are entitled to first call on all patriotic a n d istic impulse * . If something h a s neglected * let it b s clae--not these unfortunate physical wrecks who nre not demanding Aharlty but merely a market for the t h i they make with their hands and ketek. Equity investors alike have grown wary of investing in early-stage biotech concerns, no matter how promising their premise or how many stellar scientists they employ. The markets are interested in products and in companies with a near-term prospect of profitability. Pure innovation -- research without the potential for immediate commercialization -- has little luster. Today, after a peak of excitement fueled by the Human Genome Project, valuations of biotech companies are down. With dollars flowing only to later-stage ventures, most biotech companies have cut back or eliminated their own investment in basic research. And the large pharmaceutical companies, consumed by a wave of consolidation and driven by the financial markets to develop "blockbuster" drugs, have not been inclined to finance innovative biomedical research. These developments would be tragic, for medicine and humankind, were it not for the thousands of research scientists plugging away in their labs in academia -- and independent institutes like the Salk.

Kato excavator parts

Kato union pacific

Kato v12, kato ballroom, kato polymer clay, kato excavator parts and kato union pacific. Discount kato, kato unitrack, kato drug and kato 4400 or kato 30thc.